Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Consulting agrmnt
AKCEA THERAPEUTICS, INC. (AKCA) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/18/2020 8-K Appointed a new director
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 18, 2020 Akcea Therapeutics, Inc. Delaware 001-38137 47-2608175 22 Boston Wharf Road 9th Floor Boston, MA 02210 Registrant's Telephone Number, Including Area Code: 207-0202 Not Applicable Title of each class Trading Symbol Name of each exchange on which registered Common stock AKCA NASDAQ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Ac...",
"Michael D. Price Offer Letter",
"Michael D. Price Severance Benefit Agreement",
"Akcea Announces Appointment of New Chief Financial Officer"
06/05/2018 8-K Appointed a new director
Docs: "Akcea Therapeutics Appoints Industry Leader Dr. Richard Moscicki to Board of Directors"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy